Rhinacanthin-C mediated herb-drug interactions with drug transporters and Phase I drug metabolizing enzymes.

Wilasinee Dunkoksung, Nontima Vardhanabhuti, Pongpun Siripong and Suree Jianmongkol

Department of Pharmacology and Physiology (W.D. and S.J.); Department of Pharmaceutics and Industrial Pharmacy (N.V.), Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
National Cancer Institute, Bangkok, Thailand (P.S.).
Running Title Page

Running title: Interaction of rhinacanthin-C with transporters and CYP450s

Corresponding author: Suree Jianmongkol, Ph.D.
Department of Pharmacology and Physiology,
Faculty of Pharmaceutical Sciences,
Chulalongkorn University,
Payathai Rd., Pathumwan, Bangkok 10330, THAILAND
TEL +662 218 8318, FAX: +662 218 8324,
E-mail: suree.j@pharm.chula.ac.th

Number of text pages = 18
Number of tables = 5
Number of figures = 7
Number of references = 56
Number of words in Abstract = 243
Number of words in Introduction = 677
Number of words in Discussion = 1,669

Abbreviations:

AP-to-BL, apical-to-basolateral; BCRP, breast cancer resistance protein; BL-to-AP, basolateral-to-apical; Caco-2, human colon adenocarcinoma cells; CYP or CYP450, cytochrome P450; DDI, drug-drug interaction; ER, efflux ratio; HEK293, human embryonic kidney cells; HLMs, human liver microsomes; MDCKII, Madin-Darby Canine Kidney II cells; OATP, organic anion-transporting polypeptide; P_app, apparent permeability coefficients; P-gp, P-glycoprotein; UHPLC-MS/MS, ultrahigh pressure liquid chromatography-tandem mass spectrometry; US FDA, U.S. Food and Drug Administration
Abstract

Rhinacanthin-C is a major active constituent in *Rhinacanthus nasutus* (L.) Kurz, a plant widely used in herbal remedies. Its potential for pharmacokinetic herb-drug interaction may exist with drug transporters and drug metabolizing enzymes. This study assessed the possibility for rhinacanthin-C mediated-drug interaction by determining its inhibitory effects against major human efflux and influx drug transporters as well as various human CYP450 isoforms. Rhinacanthin-C demonstrated a moderate permeability through the Caco-2 monolayers ($P_{app}$ (AP-to-BL) = $1.26 \times 10^{-6}$ cm/s). It significantly inhibited both P-gp ($IC_{50} = 5.20$ µM) and BCRP ($IC_{50} = 0.83$ µM) mediated transport across Caco-2 and BCRP-overexpressing MDCKII cells. This compound also strongly inhibited OATP1B1 ($IC_{50} = 0.70$ µM) and OATP1B3 ($IC_{50} = 3.95$ µM) mediated uptake in OATP1B-overexpressing HEK cells. In addition to its inhibitory effect on these drug transporters, rhinacanthin-C significantly inhibited multiple human CYP450 isoforms including CYP2C8 ($IC_{50} = 4.56$ µM), 2C9 ($IC_{50} = 1.52$ µM), 2C19 ($IC_{50} = 28.40$ µM), and 3A4/5 ($IC_{50} = 53$ µM for midazolam and $IC_{50} = 81.20$ µM for testosterone), but not CYP1A2, 2A6, 2B6, 2D6, and 2E1. These results strongly supported a high propensity for rhinacanthin-C as a perpetrator of clinical herb-drug interaction via inhibiting various influx and efflux drug transporters (i.e., P-gp, BCRP, OATP1B1, and OATP1B3) and CYP450 isoforms (i.e., CYP2C8, CYP2C9, and CYP2C19). Thus, the potential for significant pharmacokinetic herb-drug interaction should be addressed when herbal products containing rhinacanthin-C are to be used in conjunction with other prescription drugs.
Introduction

Herbal products have been used increasingly worldwide either as alternative medicines or dietary supplements. Co-administration of these products with therapeutic agents potentially leads to herb-drug interaction via pharmacokinetic interference on drug metabolism and/or transport (Oga et al., 2016; Sprouse and van Breemen, 2016; Wu et al., 2016). The common interference mechanisms involve inhibition and induction of drug metabolizing enzymes and drug transporters. Consequently, both therapeutic efficacy and safety can be affected (Zhou et al., 2007; Oga et al., 2016).

The superfamily of cytochrome P450 (CYPs) enzymes; particularly CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5; is the major drug metabolizing enzymes in phase I oxidative metabolism. These expressed CYPs in the liver and extrahepatic tissues (i.e. intestine) are attributed to metabolism of approximately 70% of drugs and exogenous substances in human (Wienkers and Heath, 2005). When taken orally, CYP substrates are metabolized by intestinal CYPs as well as hepatic CYPs. Both intestinal and hepatic metabolism will affect drug absorption and disposition, resulting in decreased bioavailability and altered pharmacokinetic profiles of those substrate drugs (Wienkers and Heath, 2005; Xie et al., 2016). Moreover, drugs that are subjected to CYPs metabolism are at high risk to drug-drug interaction when orally co-administered with CYP inhibitors. If CYP inhibitors are present in the gastrointestinal tract at high concentrations, they can effectively inhibit intestinal CYP-mediated metabolism of concomitant substrate drugs. In addition, if these inhibitors can reach the liver at high levels, they can also interfere hepatic drug metabolism. This will lead to even higher plasma drug concentrations and alteration in therapeutic responses may be anticipated.
with narrow therapeutic index such as phenytoin and warfarin are more vulnerable to such drug-drug interaction (Miners and Birkett, 1998). Moreover, efflux transporters (e.g., breast cancer resistance protein, BCRP; Multidrug resistance-associated proteins (MRPs); P-glycoprotein, P-gp) and influx transporters (e.g., organic anion-transporting polypeptides, OATPs) also play important roles in drug absorption and disposition (Mizuno et al., 2003; König et al., 2013). These transporters are located in various organs including intestine, liver, and kidney. Several popularly used herbal products such as St. John’s wort, echinacea, goldenseal, grapefruit juice, ginseng and milk thistle are potent inhibitors or modulators of various CYP enzymes and transporter proteins (Gurley et al., 2005; Brantley et al., 2014). Clinically, the incidence of CYP-transporter-based drug interactions from herb-mediated pharmacokinetic alteration of prescription medicines has been reported (Oga et al., 2016; Sprouse and van Breemen, 2016). Hence, investigation of potential herb-drug interaction relating to CYP enzymes and transporters is necessary to support efficacy and safety of therapeutic agents in concurrent use with herbal products.

*Rhinacanthus nasutus* (L.) Kurz (Acanthaceae) has long been used in traditional medicines in the tropical region including India, Taiwan, South China, and Thailand. The plant has been used to treat various symptoms such as fever, fluid retention, hypertension, pneumonia, hepatitis, diabetes, and cancers (Siripong et al., 2006a, b; Horii et al., 2013). Rhinacanthin-C (Fig. 1) is a major bioactive naphthoquinone constituent found in this plant (Sendl et al., 1996; Siripong et al., 2006a, b; Panichayupakaranant et al., 2009). Recently, we demonstrated that rhinacanthin-C significantly enhanced doxorubicin-mediated cytotoxicity in vitro via inhibition of MRP2 and P-gp efflux transporters (Wongwanakul et al., 2013; Chaisit et al., 2017). In addition to its effect on efflux transporters, this naphthoquinone...
compound exerts inhibitory effect on a few CYP450 enzymes (i.e., CYP2A6 and 2A13) (Pouyfung et al., 2014). Thus, it can be anticipated that rhinacanthin-C may cause herb-drug pharmacokinetic interaction when concurrently used with CYP/transporter drug substrates. Until now, there are no reports on rhinacanthin-C inhibition against P-gp, BCRP and OATP drug transporters as well as against human CYP450 enzymes particularly those involved in drug metabolism.

This study aims to assess the potential herb-drug interaction caused by rhinacanthin-C when taken orally. The intrinsic properties of this compound as a perpetrator to interfere with drug absorption and disposition via drug transporters and Phase I drug metabolizing enzymes were examined. The results of this mechanistic study on drug interaction was also used as a basis to predict the potential clinical pharmacokinetic interference between rhinacanthin-C and other co-administered drugs.

Materials and methods

Materials and Chemicals. Rhinacanthin-C was isolated from the root of *Rhinacanthus nasutus* (L.) Kurz (*R. Nasutus*), purified and identified as previously described (Siripong et al., 2006a, b). Other chemicals including acyclovir, amodiaquin dihydrochloride dihydrate, atenolol, dextromethorphan hydrobromide, KO143, propranolol, tolbutamide, valspodar, and Hanks’ Balanced Salt solution (HBSS) were purchased from Sigma Chemical Company (St Louis, MO, USA). Bupropion hydrochloride, chlorzoxazone, coumarin, digoxin, digitoxin, doxazosin mesylate, ketoconazole, β-nicotinamide adenine dinucleotide phosphate (NADPH), orphenadrine hydrochloride, phenacetin, prazosin hydrochloride, and testosterone were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). 8-fluorescein-cAMP (8-FcA) was obtained from Biolog Life Science Institute (Bremen,
Germany). (S)-Mephenytoin was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Midazolam was purchased from Cerilliant Corporation (Round Rock, TX, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), Geneticin (G418), GlutaMax, L-glutamine, and minimal essential medium (MEM) were from Gibco Life Technologies (Grand Island, NY, USA). Fetal Bovine Serum (FBS) was from Biochrom AG (Berlin, Germany). Hygromycin and pooled human liver microsomes (HLMs) from 50 donors were obtained from Invitrogen (Carlsbad, CA, USA). All other reagents were of high performance liquid chromatography (HPLC) or analytical grade. Transwells (12 mm diameter, 0.4 μm pores) and 24-well plates coated with 0.1 mg/ml poly-D-lysine were purchased from Corning Incorporated (Corning, NY, USA).

Cell cultures. The human colon adenocarcinoma (Caco-2, ATCC®, HTB37™) cell line was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were cultured in DMEM containing 10% FBS, 1% NEAA, 1% L-glutamine and 1% penicillin/streptomycin solution at 37 °C in a humidified atmosphere of 5% CO₂. For the transport assays, cells (passage numbers 40 to 60) were seeded at a density of 6.0 x 10⁴ cells/cm² onto Transwell inserts and cultured for 21 days. The integrity of cell monolayers was evaluated by measuring the transepithelial electrical resistance (TEER) with a Millicell-ERS® (Millipore Corporation, Bedford, MA, USA). Only Caco-2 monolayers having TEER values above 600 Ωcm² were used in our experiments.

The polarized Madin-Darby Canine Kidney II (MDCKII) parental cell line and subclone transduced with human BCRP (MDCKII-BCRP) were kind gifts from Dr. Alfred H. Schinkel (The Netherlands Cancer Institute, Amsterdam, Netherlands). The cells were maintained in DMEM containing 10% FBS, 1% GlutaMax and 0.5%
penicillin/streptomycin solution in a humidified atmosphere of 5% CO₂ at 37 °C. For transport assays, cells were seeded at a density of 21.4 x 10⁴ cells/cm² onto Transwell® inserts and grown for 3 days. The cell monolayers with TEER values above 200 Ωcm² were used in our experiments.

The human embryonic kidney (HEK293) cells stably over-expressing human OATP1B1 (HEK-OATP1B1), human OATP1B3 (HEK-OATP1B3) as well as the vector control cell lines HEKCo/G418 and HEK-Co/Hygromycin were kind gifts from Dr. Jörg König (Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany). Cells were cultured in 10% FBS-MEM containing either geneticin or hygromycin at 37 °C, as previously described (König et al., 2011; 2012). For uptake assays, cells were seeded at densities of 12.5 x 10⁴ cells/cm² (for HEK-OATP1B1 and HEKCo/G418) and 8.0 x 10⁴ cells/cm² (for HEK-OATP1B3 and HEK-Co/Hygromycin) onto poly-D-lysine coated plates and grown to their confluence for 3 days. The cells were further cultured in the presence of 10 mM sodium butyrate for 1 day and used for the uptake experiment (König et al., 2011).

**Permeability assays.** Permeability assays were performed as previously described (Dunkoksung et al., 2019; Hubatsch et al., 2007). The Caco-2 monolayers were treated with 10 mM HEPES-HBSS (pH 7.4) containing either rhinacanthin-C or a cocktail mixture of three permeability markers (10 µM acyclovir, 10 µM atenolol, and 10 µM propranolol) in the apical (AP) site at 37 °C for 3 h. Samples were collected from the basolateral (BL) side every 30 min with fresh buffer replacement. The collected samples were mixed with an equal volume of 100% acetonitrile containing the internal standard (75 nM labetalol for permeability markers; 1.25 µM
menadione sodium bisulfate for rhinacanthin-C). After centrifugation (12,000 X g for 10 min, 4 °C), the supernatants were analyzed by UHPLC-MS/MS.

**P-gp and BCRP substrate assays.** The bidirectional transports (AP to BL and BL to AP directions) of rhinacanthin-C were determined across cell monolayers (Caco-2 monolayers for P-gp; MDCKII-BCRP/MDCKII-parental monolayers for BCRP) at 37 °C, using a protocol described previously (Hubatsch et al., 2007; Poller et al., 2011; Dunkoksung et al., 2019). Rhinacanthin-C was added to either the AP or the BL chamber, depending on the transport direction studied. A known substrate of each transporter (P-gp substrate digoxin, 5 μM; BCRP substrate prazosin, 5 μM) was used as a positive control group. Samples were taken from the relevant chamber every 30 min for 180 min and mixed with an equal volume of 100% acetonitrile containing internal standard of each compound (2 μM digitoxin for digoxin, 60 nM doxazosin for prazosin, 1.25 μM menadione sodium bisulfate for rhinacanthin-C). After centrifugation, the supernatants were analyzed by UHPLC-MS/MS.

**P-gp and BCRP inhibition assays.** The inhibitory action of rhinacanthin-C on either P-gp or BCRP activity was determined in the bidirectional transport assays as described above. The cell monolayers were treated with probe P-gp or BCRP substrates (digoxin, 5 μM; prazosin, 5 μM) in the presence or absence of rhinacanthin-C. Samples were collected from the relevant chamber every 30 min for 180 min and mixed with an equal volume of 100% acetonitrile containing the internal standard. After centrifugation, the supernatants were quantified for digoxin and prazosin by UHPLC-MS/MS analysis. Known inhibitors of each transporter [valspodar and ketoconazole (P-gp inhibitors); KO143 (BCRP inhibitor)] were used as positive control groups.
**OATP1B1 and OATP1B3 inhibition assays.** The inhibitory action of rhinacanthin-C on either OATP1B1 or OATP1B3 activities was determined in the uptake assay with a protocol described previously (Seithel et al., 2007; Bednarczyk, 2010). Cells (HEK293-OATP1B1, HEK293-OATP1B3 and respective vector control cell lines) were treated with rhinacanthin-C for 30 min at 37 °C, followed by addition of the probe substrate 8-FcA at a concentration of 2.5 μM for OATP1B1 or 1.25 μM for OATP1B3 for another 10 min. The treated cells were washed with ice-cold HBSS and lysed with methanol/10 mM Tris solution (1:1) containing 1 mM EDTA. The fluorescent intensity of 8-FcA was determined with a microplate reader (Wallac 1420 VICTOR 3, PerkinElmer Inc., MA, USA) at 485/535 nm (excitation/emission wavelengths). Cyclosporin A and rifampicin (known OATP1B1/OATP1B3 inhibitors) were used as positive control groups.

**CYP450 cocktail inhibition assays.** The inhibitory action of rhinacanthin-C on CYP enzymes in HLMs were determined as previously described (Li et al., 2015). HLMs (0.2 mg/mL, final concentration) were incubated with a cocktail of CYP substrates and rhinacanthin-C in 0.1 M phosphate buffer (pH 7.4) containing 3.3 mM MgCl₂ at 37 °C. The concentration of HLMs was kept at 0.2 mg/ml to minimize nonspecific binding to HLMs (Obach, 2008). The cocktail preparation of CYP substrates contained 100 μM phenacetin (CYP1A2), 1.5 μM coumarin (CYP2A6), 12 μM bupropion (CYP2B6), 1 μM amodiaquine (CYP2C8), 100 μM tolbutamide (CYP2C9), 50 μM (S)-mephenytoin (CYP2C19), 2.5 μM dextromethorphan (CYP2D6), 15 μM chlorzoxazone (CYP2E1), 2.5 μM midazolam, and 50 μM testosterone (CYP3A4/5). The reaction was initiated by addition of NADPH (1.3 mM, final concentration). At the end of 10 min-incubation period, the reaction was stopped with ice-cold 3% formic acid in 5% acetonitrile solution containing 0.1 μM
orphenadrine as internal standard. The samples were collected and centrifuged before UHPLC-MS/MS analysis.

**Mechanism-based CYP450 inhibition assays.** Mechanism-based inhibition of CYPs was assessed by IC$_{50}$ shift method (de Ron and Rajaraman, 2016; Haque et al., 2017). HLMs (0.2 mg/mL, final concentration) were incubated for 30 min with rhinacanthin-C in 0.1 M phosphate buffer pH7.4 containing 3.3 mM MgCl$_2$ at 37 °C in the presence and absence of 1.3 mM NADPH. The reaction was initiated by addition of a cocktail of CYP2C8, 2C9, 2C19, and 3A4/5 substrates. At the end of 10 min-incubation period, the reaction was terminated with ice-cold 3% formic acid in 5% acetonitrile solution containing 0.1 µM orphenadrine as internal standard. The samples were collected and centrifuged before UHPLC-MS/MS analysis.

**UHPLC-MS/MS analysis.** UHPLC-MS/MS analysis was conducted on an Eksigent Ekspert ultra LC 100 with QTRAP® 6500 system (AB SCIEX, MA, USA). A rapid UHPLC gradient with an ACE® C18 column (3µm, 50 X 1.0 mm I.D.) was used to perform a quick reverse-phase separation (10-95% ACN with 0.1% formic acid for all metabolites, rhinacanthin-C and prazosin; 20-95% ACN with 2 mM ammonium formate for digoxin). The flow rate was set at 200 µL/min and the column oven temperature at 45 °C. The injection volume was either 5 µL (prazosin) or 10 µL (all metabolites, rhinacanthin-C and digoxin). Detection was carried out using electrospray ionization (ESI) with polarity switching, collision-induced dissociation and selected reaction monitoring. The mass transitions of the metabolites, digoxin (ammonium adduct), prazosin, rhinacanthin-C and internal standards are listed in Tables 1 and 2.
**Calculation.** For the transport assays, the apparent permeability coefficients, $P_{\text{app}}$ (cm/s), for both AP to BL and BL to AP directions of each test compound were calculated from the following equation:

$$P_{\text{app}} = \left( \frac{\text{d}Q}{\text{d}t} \right) \times \left( \frac{1}{C_0 A} \right)$$

Where $\text{d}Q/\text{d}t$ is the cumulative transport rate (nmol/min), $C_0$ is the initial drug concentration on the drug-introducing side (μM), and $A$ is the surface area of the inserts (1.12 cm$^2$ in 12-wells). The efflux ratio (ER) was the ratio of $P_{\text{app(BL-to-AP)}}$ to $P_{\text{app(AP-to-BL)}}$.

**Data analysis.** Quantitative UHPLC-MS/MS data were analyzed using MultiQuant™ Software (AB SCIEX, MA, USA). The 50% inhibitory concentration (IC$_{50}$) values were calculated from non-linear regression analysis using SigmaPlot version 14.0 (Systat Software, San Jose, CA, USA). Data were presented as mean ± S.E. Data were obtained from three or four separated experiments. Statistical analysis was performed by either the Student’s $t$ test or the one-way analysis of variance (ANOVA), followed by the post-hoc Tamhane’s T2 test. Statistical significance was considered at $p < 0.05$.

**Results**

**Permeability of rhinacanthin-C across Caco-2 cell monolayer.** Three permeability markers namely acyclovir, atenolol and propranolol (low, moderate, and high permeability, respectively) were chosen as our references, based on the U.S. Food and Drug Administration (US FDA) recommendation (US FDA, 2017a). The $P_{\text{app}}$ values across Caco-2 cell monolayers in the absorptive direction (AP-to-BL) of the three reference markers in ascending order were $0.06 \pm 0.01 \times 10^{-6}$ cm/s (acyclovir, 10 μM), $0.48 \pm 0.06 \times 10^{-6}$ cm/s (atenolol, 10 μM) and $19.25 \pm 0.99 \times 10^{-6}$ cm/s (propranolol, 10 μM). The $P_{\text{app}}$ (AP-to-BL) of rhinacanthin-C (10 μM) was $1.26 \pm$
0.07 × 10⁻⁶ cm/s, suggesting that its permeability was likely in the same rank order with atenolol (moderately permeable compound).

**P-gp and BCRP substrate assays.** Expression of either P-gp in Caco-2 monolayers or BCRP in MDCKII-BCRP monolayers was clearly demonstrated by the bidirectional transport of specific probe substrates (digoxin, P-gp substrate; prazosin, BCRP substrate) and inhibitors (valspodar, ketonazole, P-gp inhibitors; KO143, BCRP inhibitor) (Fig. 2, 3). The efflux ratio of digoxin (5 µM) across Caco-2 monolayers significantly decreased by approximately 10-fold in the presence of the positive control P-gp inhibitors (valspodar, 1 µM; ketonazole, 25 µM) (Fig. 2). The known BCRP inhibitor KO143 (1 µM) significantly hindered permeation of prazosin (5 µM) across MDCKII-BCRP monolayers by approximately 4-fold, but not in the MDCKII-control cell monolayers (Fig. 3, A and B).

Permeability of rhinacanthin-C in the absorptive direction ($P_{\text{app (AP-to-BL)}}$) across Caco-2 monolayers increased, without any significant change in $P_{\text{app (BL-to-AP)}}$, upon increasing its concentration from 10 µM to 100 µM (Fig. 2). Consequently, the calculated efflux ratio of this compound somewhat decreased from 2.27 ± 0.28 (10 µM) to 0.88 ± 0.09 (100 µM). This result suggested that rhinacanthin-C could be a weak P-gp substrate. On the other hand, the permeability profiles of rhinacanthin-C (10, 100 µM) across MDCKII-BCRP and MDCKII-control monolayers were comparable, with the efflux ratio values of less than 2, suggesting that rhinacanthin-C is not a substrate for BCRP (Fig. 3, A and B).

**P-gp and BCRP inhibition by rhinacanthin-C.** The abilities of rhinacanthin-C to inhibit P-gp and BCRP activities were assessed by determining the net flux of digoxin and prazosin across cell monolayers. Rhinacanthin-C was able to inhibit both P-gp-mediated transport of digoxin and BCRP-mediated transport of prazosin in
a concentration-dependent manner, with IC\textsubscript{50} values of 5.20 ± 0.44 µM and 0.83 ± 0.09 µM, respectively (Fig. 4, A and B; Table 3). Our results suggested that rhinacanthin-C was approximately 6-fold more selective for BCRP than for P-gp. At 10 µM, rhinacanthin-C inhibited transport of digoxin across Caco-2 monolayers by 64%, and transport of prazosin across MDCKII-BCRP monolayers by 75%.

**OATP1B1 and OATP1B3 inhibition by rhinacanthin-C.** Inhibition of OATP1B1 and OATP1B3 by rhinacanthin-C was investigated by monitoring the uptake of probe substrate 8-FcA in HEK293 cell line heterologously expressing the human OATP1B1 or OATP1B3. Under our condition, the positive control inhibitor cyclosporin-A inhibited OATP1B1 and OATP1B3 with IC\textsubscript{50} values of 0.71 ± 0.19 µM and 0.31 ± 0.11 µM, respectively. In addition, rifampicin inhibited OATP1B1 and OATP1B3 with IC\textsubscript{50} values of 1.44 ± 0.49 µM and 1.47 ± 0.52 µM, respectively. Rhinacanthin-C was able to inhibit both OATP1B1- and OATP1B3-mediated uptake of 8-FcA in a concentration-dependent manner (Fig. 5, A and B). This compound inhibited OATP1B1 with IC\textsubscript{50} values of 0.70 ± 0.12 µM and inhibited OATP1B3 with IC\textsubscript{50} values of 3.95 ± 1.36 µM (Table 3). Apparently, rhinacanthin-C was approximately 8-fold more selective for OATP1B1 than for OATP1B3. At 10 µM, rhinacanthin-C suppressed activities of OATP1B1 by 87%, and of OATP1B3 by 65%.

**CYP450 inhibition by rhinacanthin-C.** Inhibition of human CYP450 enzymes by rhinacanthin-C was investigated by measuring the metabolite formation of each selective probe substrates in HLMs (Table 2). Rhinacanthin-C inhibited the activities of CYP2C family namely CYP2C8, CYP2C9 and CYP2C19 in a concentration-dependent manner with IC\textsubscript{50} values of 4.45 ± 0.44 µM, 1.57 ± 0.22 µM and 29.40 ± 4.16 µM, respectively (Fig. 6B, Table 4). In contrast, rhinacanthin-C at all concentrations tested (0.1-50 µM) did not inhibit the activities of CYP1A2,
CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4/5 (IC$_{50}$ > 50 µM) (Fig. 6, A, C and D; Table 4). Since CYP3A4/5 is highly expressed in enterocytes, where high concentrations of rhinacanthin-C would be anticipated, the inhibition study of CYP3A4/5 by rhinacanthin-C was carried out at an expanded concentration range (1-100 µM) in HLMs. Rhinacanthin-C was able to inhibit CYP3A4/5-mediated transformation of midazolam and testosterone with IC$_{50}$ values of 53.00 ± 4.22 µM and 81.20 ± 6.42 µM, respectively (Fig. 6D).

The mechanism-based CYP450 inhibition by rhinacanthin-C. The IC$_{50}$ ratio was obtained from the ratio of the IC$_{50}$ values of rhinacanthin-C in the absence of NADPH and in the presence of NADPH during 30 min-preincubation. As shown in Fig. 7, the IC$_{50}$ values of rhinacanthin-C-mediated inhibition of CYP2C family were comparable in the absence and presence of NADPH in the preincubating reaction mixture, resulting in the IC$_{50}$ ratio values of 1 (0.61 ± 0.07 – 1.12 ± 0.34) (Fig. 7, A-C; Table 5). It is worth noting that rhinacanthin-C in the preincubating reaction mixture with NADPH was apparently more potent than that without NADPH in reducing CYP3A4/5-mediated metabolism of testosterone, resulting in the IC$_{50}$ ratio value of 1.97 ± 0.44 (Fig. 7E, Table 5). However, the effect of NADPH was not observed when midazolam was used as CYP3A4 substrate in place of testosterone. The IC$_{50}$ ratio of rhinacanthin-C for CYP3A4/5 (midazolam as the substrate) was less than 1 (Fig. 7D, Table 5).

Discussion

Rhinacanthin-C is a major active constituent in *R. Nasutus*, which has been commonly used in complementary therapy for various symptoms such as fever, fluid retention, hypertension, pneumonia, hepatitis, diabetes, and cancers (Siripong et al. 2006a, b; Horii et al., 2013; Shah et al., 2018). It is very likely that this compound
will be taken in concomitant with several other drug substances, leading to herb-drug interaction issues (Horii et al., 2013; Shah et al., 2018). In the present study, we assessed the potential for rhinacanthin-C as a perpetrator in herb-drug interaction via modulation of drug metabolizing enzymes and transporters. To be a perpetrator in herb-drug interaction, a compound needs to be significantly absorbed through the gastrointestinal (GI) epithelium (Zhou et al., 2007; Sprouse and van Breemen, 2016). Our study showed that rhinacanthin-C was not a substrate for P-gp and BCRP efflux transporters. In addition, it demonstrated moderate permeability through the model GI membrane when compared to the FDA-recommended bioavailability markers (US FDA, 2017a). Thus, this compound could function as a perpetrator if it interfered with the metabolizing enzymes and transporters.

The intestinal efflux transporters play important roles in oral bioavailability and tissue distribution of their substrate drugs (Misaka et al., 2013; Wu et al., 2016). In addition, the liver also expresses high levels of CYP enzymes and influx transporters (Wienkers and Heath, 2005; König et al., 2013). The inhibitory potential of rhinacanthin-C on these enzymes and transporters in the hepatic and other organs will result in alteration in the pharmacokinetic profile of the co-administered drug. Our results suggested that rhinacanthin-C was capable of selective inhibiting drug transporters and multiple CYP450 isoforms.

Rhinacanthin-C was capable of inhibiting both efflux and influx transporters including P-gp, BCRP, OATP1B1, and OATP1B3. Inhibition of intestinal P-gp or BCRP efflux transporters has been correlated to increase bioavailability and plasma concentration of their substrate drugs such as topotecan (Pgp/BCRP), paclitaxel, digoxin, indinavir (P-gp) and rosuvastatin (BCRP) (Kruijtzer et al., 2002; Hendrikx et al., 2013; Misaka et al., 2013; Elsby et al., 2016). Recently, we reported that
rhinacanthin-C could interfere with P-gp function in the Caco-2 and MCF-7 cells models (Wongwanakul et al., 2013; Chaisit et al., 2017). In this study, rhinacanthin-C displayed higher potency and selectivity for BCRP as compared to P-gp in the bidirectional transport assay, with the IC₅₀ values of 0.83 µM (BCRP) and 5.20 µM (P-gp), respectively. We further assessed its perpetrator potential to mediate in vivo intestinal efflux transporter-based interaction by calculating the Iₙ/gut/IC₅₀ ratio values (Table 3) (US FDA, 2017b). Given that the recommended dose of *R. nasutus* capsule (rhinacanthin-C content ~ 0.47-1.90% w/w) is 900 mg, the intestinal amount of rhinacanthin-C may range approximately from 4.27 to 17.10 mg in 250 ml GI volume (Gotoh et al., 2004; Panichayupakaranant et al., 2009). The in vitro calculated Iₙ/gut/IC₅₀ values for BCRP was > 50, suggesting a high risk of in vivo herb-drug interaction arising from rhinacanthin-C-mediated inhibition of intestinal BCRP (US FDA, 2017b). In addition, a potential in vivo drug interaction associated with rhinacanthin-C mediated-intestinal P-gp inhibition also existed (Iₙ/gut/IC₅₀ ratios ranging from 8 – 32; Table 3), depending upon the dose of *R. nasutus* and its rhinacanthin-C content.

The inhibitory effects of rhinacanthin-C against OATP1B1 and OATP1B3 influx transporters were also evaluated. This compound demonstrated higher potency and selectivity for OATP1B1 (IC₅₀ = 0.70 µM) than for OATP1B3 (IC₅₀ = 3.95 µM). The inhibitory potency of rhinacanthin-C was quite comparable with that of the known OATP1B1 inhibitor cyclosporin A (IC₅₀ = 0.71 µM). Both OATP1B1 and OATP1B3 influx transporters are highly expressed in liver and play important roles in drug disposition (König et al., 2013). Inhibition of these two influx transporters results in an increased plasma concentration of their drug substrates such as pitavastatin, pravastatin, fexofenadine, and methotrexate (Kalliokoski and Niemi,
2009; König et al., 2013). Hence, our results support a high potential for rhinacanthin-C to cause clinically significant drug interaction with several drugs that are substrates of multiple drug transporters such as digoxin, doxorubicin (P-gp substrate), atorvastatin, rosuvastatin, and simvastatin (BCRP and OATP substrates).

Inhibition of CYPs-mediated metabolism can be attributed to as high as 70% of drug interaction issues (Han et al., 2011). In this study, we assessed the inhibitory potential of rhinacanthin-C on nine CYP isoforms (i.e., CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5) in HLMs. Our data clearly showed that rhinacanthin-C strongly inhibited several CYP2C isoforms (CYP2C8, IC_{50} 4.45 µM; CYP2C9, IC_{50} 1.57 µM; CYP2C19, IC_{50} 29.40 µM), but not CYP1A2, CYP2A6, CYP2B6, CYP2D6, and CYP2E1. Although rhinacanthin-C was previously reported to inhibit reconstituted recombinant CYP2A6 (Pouyfung et al., 2014), we did not detect its CYP2A6 inhibition in our HLMs-based assay system. This disparity may be attributed to the difference in CYP functionality in the enzyme sources used (i.e., recombinant CYP versus HLMs). Critical differences in the sensitivity to detect time-dependent CYP inactivation arose from different enzyme sources were recently reported (Di et al., 2007; Kahma et al., 2019). The inhibitory action of rhinacanthin-C against CYP2C isoforms was NADPH-independent, suggesting a non-mechanism-based inhibition. Nevertheless, we could not rule out the possibility that rhinacanthin-C might be a substrate of these CYP isoforms. In addition, this compound demonstrated weak inhibitory effect against CYP3A4/5 with the IC_{50} values of 53 µM (midazolam, substrate) and 81 µM (testosterone, substrate). It is interesting to note that rhinacanthin-C-mediated inhibition of testosterone metabolism was NADPH-dependent, suggesting mechanism-based inhibition (IC_{50} ratio = 1.97, Table 5) (Haque et al., 2017). However, this NADPH-
dependent CYP3A4/5 inhibition was not observed when midazolam was used as CYP3A4/5 substrate (IC$_{50}$ ratio < 1, Table 5) (Haque et al., 2017). These findings indicate that rhinacanthin-C had low risk for herb-drug interaction via CYP3A4/5.

Our results suggested that potential risk of herb-drug interaction arising from rhinacanthin-C-mediated CYP-inhibition is likely to associate with inhibition of CYP2C9. Inhibition of CYP2C9 could affect metabolism of its drug substrates such as (S)-warfarin, tolbutamide, and phenytoin (van Booven et al., 2010). Inactivation of CYP2C9 by desethylamiodarone (IC$_{50}$ = 5.5 µM) was reported to be a major contribute to drug interaction between (S)-warfarin and amiodarone, leading to an increased plasma concentration of (S)-warfarin and risk of hemorrhage (Heimark et al., 1992; McDonald et al., 2012). It is very likely that rhinacanthin-C is capable of interfering CYP2C9-mediated metabolism of its substrate drugs when used concurrently.

CYP2C9 is primarily expressed in the liver and intestine (Paine et al., 2006). However, its catalytic activity and content in the intestine are known to be an order of magnitude lower than those in the liver. Though the intestinal CYP2C9 has a low contribution to first-pass metabolism of substrate drugs, this enzyme shows large interindividual variability in its activity and content (Paine et al., 2006; Xie et al., 2016). Thus, CYPs inhibitors may cause drug interaction via intestinal CYP2C9 in some individuals, especially in cases of low oral bioavailability substrate drugs (Paine et al., 2006; Xie et al., 2016). For example, co-administration of fluvastatin with CYP2C9 inhibitors (e.g. ranitidine, cimetidine, and omeprazole) increased the bioavailability of fluvastatin (Scripture and Pieper, 2001). Based on the basic likelihood drug-drug interaction model of CYP inhibition, the predicted ratio (R) can be calculated from $1 + (I_{\text{max,u}} / K_i)$, where $I_{\text{max,u}}$ is the maximum unbound plasma
concentration of rhinacanthin-C and \( K_i \) is the in vitro unbound inhibition constant (US FDA, 2017b). The \( K_i \) value of 0.79 \( \mu M \) was estimated from Cheng-Prusoff equation for competitive inhibition, \( K_i = IC_{50}/(1+[S]/K_m) \) (Hutzler et al., 2011). Given that the in vivo CYP inhibition is likely to occur if \( R \geq 1.02 \) (US FDA, 2017b), the maximum plasma concentration of rhinacanthin-C should be less than 0.016 \( \mu M \) to prevent drug interaction issues with co-administered CYP2C9 substrate drugs. However, there is currently no information on plasma concentration of rhinacanthin-C available. Thus, in vivo herb-drug interaction from this compound at the liver could not be predicted. On the other hand, in our study the expected concentration of rhinacanthin-C in the intestine was as high as 26-fold of its IC\(_{50}\) value for CYP2C9 and herb-drug interaction at the intestinal site could be anticipated.

Rhinacanthin-C may contribute to therapeutic efficacy of \( R. Nasutus \) (Sendl et al., 1996; Siripong et al., 2006a, b; Panichayupakaranant et al., 2009). However, a potential safety risk stemmed from herb-drug interaction may also exist when this natural substance is co-administered with drug substrates of CYP2C family, OATP1B1/ OATP1B3 influx transporters, and P-gp/BCRP efflux transporters. Risk of adverse events may increase when those drug substrates are in the “narrow therapeutic” drug group such as digoxin (P-gp substrate), warfarin and phenytoin (CYP2C9 substrate) (van Booven et al., 2010; Misaka et al., 2013). In addition, several drugs can be substrates of both CYP450 enzymes and drug transporters. For example, repaglinide is a substrate of CYP2C8 and OATP1B1 (Bidstrup et al., 2003). Pitavastatin and rosuvastatin are known substrates of OATPs, BCRP and CYP2C9 (Causevic-Ramosevac and Semiz, 2013; Hu and Tomlinson, 2014). Clinical pharmacokinetic drug interaction arising from CYPs and OATPs inhibition was reported in a case of combination use of gemfibrozil (CYP2C8 and OATP1B1
inhibitor) and cerivastatin (CYP2C8 and OATP1B1 substrate) (Backman et al., 2002; Shitara et al., 2004). Gemfibrozil and its metabolites increased plasma concentration of cerivastatin via inhibiting both CYP2C8-mediated cerivastatin metabolism and OATP1B1-mediated cerivastatin hepatic uptake, leading to high risk of rhabdomyolysis (Backman et al., 2002; Shitara et al., 2004). Since rhinacanthin-C was able to inhibit multiple CYP450 isoforms, the potential for significant pharmacokinetic herb-drug interaction should be aware when it is used in conjunction with other drugs that are substrates for these enzymes. Special attention should be directed toward those that are substrates of CYP2C8, CYP2C9 and CYP2C19.

In conclusion, this in vitro study revealed that rhinacanthin-C is capable of inhibiting multiple efflux and influx drug transporters (i.e., P-gp, BCRP, OATP1B1 and OATP1B3) and CYP450 isoforms (i.e. CYP2C8, CYP2C9, CYP2C19 and CYP3A4/5). The safety profile associated with herb-drug interaction issues from rhinacanthin-C should not be ignored. Further studies on in vivo pharmacokinetic drug interaction should be pursued to support safe use of herbal products containing rhinacanthin-C in combination with other prescription drugs.

**Acknowledgements**

We thank Chulalongkorn University Drugs and Health Products Innovation Promotion Center for their facilities.

**Authorship Contributes**

*Participated in research design*: Dunkoksung, Vardhanabhuti, Jianmongkol.

*Conducted experiments*: Dunkoksung.
Contributed new reagents or analytical tools: Dunkoksung, Siripong, Jianmongkol.

Performed data analysis: Dunkoksung.

Wrote or contributed to the writing of the manuscript: Dunkoksung, Vardhanabhuti, Jianmongkol.
References


Di L, Kerns EH, Li SQ, Carter GT (2007) Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS,
rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. *Int J Pharm* **335**:1-11.


in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8. *Drug Metab Dispos* DOI: 10.1124/dmd.118.085498. [Epub ahead of print].


Footnotes

This work was supported by the 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship and the 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund).
Figure legends

**Fig. 1.** Chemical structure of rhinacanthin-C.

**Fig. 2.** Transport of rhinacanthin-C (RN-C) across the Caco-2 monolayers from the apical-to-basolateral (AP-to-BL) direction and the basolateral-to-apical (BL-to-AP) direction. Digoxin (DGX) was used as a positive control substrate of P-gp. Valspodar (PSC 833; PSC) and ketoconazole (KCZ) were used as a positive control inhibitor of P-gp. Apparent permeability coefficients (Papp) and efflux ratio (ER) represent mean ± S.E. of three independent experiments. * p < 0.05 vs control.

**Fig. 3.** Transport of rhinacanthin-C (RN-C) across the MDCKII-BCRP (A) and MDCKII-parental monolayers (B) from the apical-to-basolateral (AP-to-BL) direction and the basolateral-to-apical (BL-to-AP) direction. Prazosin (PZ) was used as a positive control substrate of BCRP. KO143 was used as a positive control inhibitor of P-gp. Apparent permeability coefficients (Papp) and efflux ratio (ER) represent mean ± S.E. of four independent experiments. * p < 0.05 vs control.

**Fig. 4.** Inhibitory effect of rhinacanthin-C (RN-C) on P-gp-mediated digoxin transport in the Caco-2 monolayers (A) and BCRP-mediated prazosin transport in the MDCKII-BCRP monolayers (B). The BCRP-mediated transport was obtained from prazosin transport across MDCKII-BCRP divided by that across MDCKII-parental monolayers. Values are expressed as percentage of vehicle control. Each value represents the mean ± S.E. of three independent experiments.

**Fig. 5.** Inhibitory effect of rhinacanthin-C (RN-C) on OATP1B1- (A) or OATP1B3- (B) mediated 8-fluorescein-cAMP (8-FcA) uptake. The OATP1B1- or OATP1B3-mediated uptake was obtained by subtracting the uptake into respective vector control cells from that into OATP-overexpressing cells. Values are expressed as...
percentage of vehicle control. Each value represents the mean ± S.E. of three independent experiments.

**Fig. 6.** Inhibitory effect of rhinacanthin-C (RN-C) on CYP450 in HLMs. The enzyme activity is expressed as a percentage of remaining activity compared with the control containing no inhibitor. All data represent mean ± S.E. of three independent experiments. (A) CYP1A2 (●,——), CYP2A6 (○,−−), and CYP2B6 (▼,⋯⋯). (B) CYP2C8 (●,——), CYP2C9 (○,−−), and CYP2C19 (▼,⋯⋯). (C) CYP2D6 (●,—) and CYP2E1 (○,−−). (D) CYP3A4/5 (midazolam substrate) (●,——) and CYP3A4/5 (testosterone substrate) (○,−−).

**Fig. 7.** The NADPH-dependent inhibition of rhinacanthin-C (RN-C) against CYP2C8 (A), CYP2C9 (B), CYP2C19 (C), CYP3A4/5 for midazolam (D), and CYP3A4/5 for testosterone (E) with NADPH preincubation (●,——) or without NADPH preincubation (○,−−) in HLMs. The enzyme activity is expressed as a percentage of remaining activity compared with the control containing no inhibitor. All data represent mean ± S.E. of three independent experiments.
TABLE 1 Concentration and mass transition of the probe substrates, permeability markers, rhinacanthin-C and internal standards

<table>
<thead>
<tr>
<th>Transporter/Permeability marker</th>
<th>Compound</th>
<th>Concentration (µM)</th>
<th>Mass transition</th>
<th>Internal standard</th>
<th>Mass transition</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-gp substrate</td>
<td>Digoxin</td>
<td>5</td>
<td>798.309&gt;651.2 (+)</td>
<td>Digitoxin</td>
<td>782.312&gt;635.3 (+)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>798.309&gt;781.4 (+)</td>
<td></td>
<td>782.312&gt;375.0 (+)</td>
</tr>
<tr>
<td>BCRP substrate</td>
<td>Prazosin</td>
<td>5</td>
<td>384.139&gt;246.8 (+)</td>
<td>Doxazosin</td>
<td>452.161&gt;343.9 (+)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>384.139&gt;230.8 (+)</td>
<td></td>
<td>452.161&gt;289.8 (+)</td>
</tr>
<tr>
<td>Low permeability marker</td>
<td>Acyclovir</td>
<td>10</td>
<td>226.043&gt;151.8 (+)</td>
<td>Labetalol</td>
<td>329.060&gt;161.8 (+)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>226.043&gt;109.6 (+)</td>
<td></td>
<td>329.060&gt;90.9 (+)</td>
</tr>
<tr>
<td>moderate permeability marker</td>
<td>Atenolol</td>
<td>10</td>
<td>267.075&gt;144.7 (+)</td>
<td>Labetalol</td>
<td>329.060&gt;161.8 (+)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>267.075&gt;189.6 (+)</td>
<td></td>
<td>329.060&gt;90.9 (+)</td>
</tr>
<tr>
<td>High permeability marker</td>
<td>Propranolol</td>
<td>10</td>
<td>260.089&gt;116.0 (+)</td>
<td>Labetalol</td>
<td>329.060&gt;161.8 (+)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>260.089&gt;182.8 (+)</td>
<td></td>
<td>329.060&gt;90.9 (+)</td>
</tr>
<tr>
<td>Rhinacanthin-C</td>
<td>10, 100</td>
<td></td>
<td>409.100&gt;167.0 (-)</td>
<td>Menadione sodium</td>
<td>252.840&gt;80.9 (-)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>409.100&gt;97.9 (-)</td>
<td>bisulfate</td>
<td>252.840&gt;63.9 (-)</td>
</tr>
</tbody>
</table>
TABLE 2 $K_m$ values, concentration of CYP450 specific probe substrates, and mass transition for metabolites and internal standard

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Substrate</th>
<th>$K_m$ $^a$ (µM)</th>
<th>Concentration (µM)</th>
<th>Metabolite</th>
<th>Mass transition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>Phenacetin</td>
<td>112.7 ± 10.9</td>
<td>100</td>
<td>Acetaminophen</td>
<td>152.0&gt;109.7 (+)</td>
</tr>
<tr>
<td>CYP2A6</td>
<td>Coumarin</td>
<td>1.5 ± 0.2</td>
<td>1.5</td>
<td>7-Hydroxycoumarin</td>
<td>161.1&gt;133.2 (-)</td>
</tr>
<tr>
<td>CYP2B6</td>
<td>Bupropion</td>
<td>125.2 ± 14.0</td>
<td>12</td>
<td>Hydroxybupropion</td>
<td>256.1&gt;138.8 (+)</td>
</tr>
<tr>
<td>CYP2C8</td>
<td>Amodiaquine</td>
<td>1.0 ± 0.1</td>
<td>1</td>
<td>N-desethylamodiaquine</td>
<td>328.1&gt;282.9 (+)</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>Tolbutamide</td>
<td>110.7 ± 11.6</td>
<td>100</td>
<td>Hydroxytolbutamide</td>
<td>285.1&gt;186.2 (-)</td>
</tr>
<tr>
<td>CYP2C19</td>
<td>(S)-mephenytoin</td>
<td>52.5 ± 10.6</td>
<td>50</td>
<td>(±)-4’-Hydroxymephenytoin</td>
<td>235.0&gt;132.6 (+)</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>Dextromethorphan</td>
<td>2.9 ± 0.5</td>
<td>2.5</td>
<td>Dextrophan</td>
<td>258.1&gt;157.2 (+)</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>Chlorzoxazone</td>
<td>149.8 ± 12.6</td>
<td>15</td>
<td>6-Hydroxychlorzoxazone</td>
<td>186.0&gt;119.7 (-)</td>
</tr>
<tr>
<td>CYP3A4/5</td>
<td>Midazolam</td>
<td>2.7 ± 0.1</td>
<td>2.5</td>
<td>1’-Hydroxymidazolam</td>
<td>342.0&gt;324.0 (+)</td>
</tr>
<tr>
<td>Testosterone</td>
<td>50.5 ± 5.6</td>
<td>50</td>
<td></td>
<td>6β-Hydroxytestosterone</td>
<td>304.8&gt;268.9 (+)</td>
</tr>
<tr>
<td>Orphenadrine (internal standard)</td>
<td>270.8&gt;180.9 (+)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$^a$ Li et al., 2015.
TABLE 3 IC\textsubscript{50} values and I\textsubscript{gut}/IC\textsubscript{50} ratios for inhibition of drug transporters by rhinacanthin-C

<table>
<thead>
<tr>
<th>Transporter</th>
<th>Substrate</th>
<th>Concentration (µM)</th>
<th>IC\textsubscript{50} (µM)</th>
<th>I\textsubscript{gut}/IC\textsubscript{50}</th>
<th>Potential for DDI\textsuperscript{a}</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-gp</td>
<td>Digoxin</td>
<td>5.00</td>
<td>5.20 ± 0.44</td>
<td>8.00-32.06</td>
<td>Yes (intestinal)</td>
</tr>
<tr>
<td>BCRP</td>
<td>Prazosin</td>
<td>5.00</td>
<td>0.83 ± 0.09</td>
<td>50.11-200.86</td>
<td>Yes (intestinal)</td>
</tr>
<tr>
<td>OATP1B1</td>
<td>8-FcA</td>
<td>1.25</td>
<td>0.70 ± 0.12</td>
<td>n/a\textsuperscript{c}</td>
<td>n/a\textsuperscript{c}</td>
</tr>
<tr>
<td>OATP1B3</td>
<td>8-FcA</td>
<td>2.50</td>
<td>3.95 ± 1.36</td>
<td>n/a\textsuperscript{c}</td>
<td>n/a\textsuperscript{c}</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Possible DDI risk based on I\textsubscript{gut}/IC\textsubscript{50} > 10, where I\textsubscript{gut} is the intestinal luminal concentration of the interaction drug [calculated from dose (mol)/250 ml], as described in Zhang et al., 2008; Giacomini et al., 2010; US FDA, 2017b.

\textsuperscript{b}I\textsubscript{gut} of rhinacanthin-C = 41.59-166.71 µM (Gotoh et al., 2004; Panichayupakaranant et al., 2009).

\textsuperscript{c}n/a = not applicable; transporter not highly expressed in the gastrointestinal tract (Hilgendorf et al., 2007).

All data are expressed mean ± SE of three independent experiments.
TABLE 4 IC$_{50}$ values for inhibition of cytochrome P450 enzymes by rhinacanthin-C

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Substrate</th>
<th>Metabolite</th>
<th>IC$_{50}^a$ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>Phenacetin</td>
<td>Acetaminophen</td>
<td>&gt; 50</td>
</tr>
<tr>
<td>CYP2A6</td>
<td>Coumarin</td>
<td>7-Hydroxycoumarin</td>
<td>&gt; 50</td>
</tr>
<tr>
<td>CYP2B6</td>
<td>Bupropion</td>
<td>Hydroxybupropion</td>
<td>&gt; 50</td>
</tr>
<tr>
<td>CYP2C8</td>
<td>Amodiaquine</td>
<td>N-desethylamodiaquine</td>
<td>4.45 ± 0.44</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>Tolbutamide</td>
<td>Hydroxytolbutamide</td>
<td>1.57 ± 0.22</td>
</tr>
<tr>
<td>CYP2C19</td>
<td>(S)-mephenytoin</td>
<td>(±)-4′Hydroxymephenytoin</td>
<td>29.40 ± 4.16</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>Dextromethorphan</td>
<td>dextrophan</td>
<td>&gt; 50</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>Chlorzoxazone</td>
<td>6-Hydroxychlorzoxazone</td>
<td>&gt; 50</td>
</tr>
<tr>
<td>CYP3A4/5$^b$</td>
<td>Midazolam</td>
<td>1′-Hydroxymidazolam</td>
<td>53.00 ± 4.22</td>
</tr>
<tr>
<td></td>
<td>Testosterone</td>
<td>6β-Hydroxytestosterone</td>
<td>81.20 ± 6.42</td>
</tr>
</tbody>
</table>

$^a$ IC$_{50}$ values are expressed as mean ± SE of three independent experiments.

$^b$ Tested at the concentration range of 1-100 µM.
TABLE 5 IC₅₀ values and ratio for inhibition of CYP2C8, 2C9, 2C19, and 3A4/5 with and without NADPH by rhinacanthin-C

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Substrate</th>
<th>IC₅₀ (µM)</th>
<th>without NADPH preincubation</th>
<th>With NADPH preincubation</th>
<th>IC₅₀ ratio&lt;br&gt;¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C8</td>
<td>Amodiaquine</td>
<td>6.58 ± 1.22</td>
<td>10.68 ± 0.74</td>
<td>0.61 ± 0.07</td>
<td></td>
</tr>
<tr>
<td>CYP2C9</td>
<td>Tolbutamide</td>
<td>2.71 ± 0.38</td>
<td>3.99 ± 0.58</td>
<td>0.68 ± 0.05</td>
<td></td>
</tr>
<tr>
<td>CYP2C19</td>
<td>(S)-mephenytoin</td>
<td>25.03 ± 5.41</td>
<td>24.44 ± 3.79</td>
<td>1.12 ± 0.34</td>
<td></td>
</tr>
<tr>
<td>CYP3A4/5</td>
<td>Midazolam</td>
<td>32.70 ± 4.30</td>
<td>34.50 ± 1.60</td>
<td>0.94 ± 0.09</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Testosterone</td>
<td>50.60 ± 4.42</td>
<td>27.20 ± 3.26</td>
<td>1.97 ± 0.44</td>
<td></td>
</tr>
</tbody>
</table>

¹ IC₅₀ ratio was calculated by IC₅₀ value of rhinacanthin-C without NADPH preincubation divided by IC₅₀ value of rhinacanthin-C with NADPH preincubation.

All data represent mean ± SE of three independent experiments.
Figure

Fig. 1.
Fig. 2.
Fig. 3.

A

![Graph A showing P_app values for different treatments with ER values for AP to BL and BL to AP comparisons.]

B

![Graph B showing P_app values for different treatments with ER values for AP to BL and BL to AP comparisons.]

**Please note:** This article has not been copyedited and formatted. The final version may differ from this version.
Fig. 4.

A

Digoxin transport (% of control) vs. RN-C concentration (μM)

B

Prazosin transport (% of control) vs. RN-C concentration (μM)
Fig. 5.

A

8-FcA accumulation (% of control)

0 20 40 60 80 100

RN-C concentration (μM)

0.001 0.01 0.1 1 10

B

8-FcA accumulation (% of control)

0 20 40 60 80 100

RN-C concentration (μM)

0.01 0.1 1 10 100

This article has not been copyedited and formatted. The final version may differ from this version.
Fig. 6.
Fig. 7.